The South African drug manufacturer has had a number of run-ins with European authorities over the pricing of its medication. The group's share price has fallen since its high of 2015, but doubled in value since an all-time low in August 2019. The run-ins with regulatory authorities have raised questions about the governance of the company, which had an astronomical rise in its share price peak at the beginning of 2015. On concerns around governance Luresha Chetty, corporate Affairs executive at Aspen said: "Aspen, its board and management are committed to effective and robust corporate governance and compliance." Izak van Niekerk, a co-portfolio manager at Mergence, says it was "regrettable" that Aspen had to pay fines to European competition authorities.

Source: News 24 July 15, 2020 09:00 UTC